Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ZNTL [NASD]
Zentalis Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-2.30 Insider Own9.40% Shs Outstand37.96M Perf Week20.40%
Market Cap1.70B Forward P/E- EPS next Y-3.80 Insider Trans-18.84% Shs Float36.65M Perf Month13.37%
Income-85.90M PEG- EPS next Q-0.95 Inst Own92.40% Short Float6.07% Perf Quarter-14.54%
Sales- P/S- EPS this Y-116.80% Inst Trans17.07% Short Ratio5.94 Perf Half Y26.45%
Book/sh8.98 P/B4.84 EPS next Y22.10% ROA- Target Price58.33 Perf Year-
Cash/sh9.41 P/C4.62 EPS next 5Y- ROE- 52W Range22.00 - 61.29 Perf YTD-16.25%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-29.03% Beta-
Dividend %- Quick Ratio15.60 Sales past 5Y- Gross Margin- 52W Low97.73% ATR2.79
Employees110 Current Ratio15.60 Sales Q/Q- Oper. Margin- RSI (14)57.13 Volatility7.66% 7.16%
OptionableNo Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.58 Prev Close41.73
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume374.65K Price43.50
Recom1.30 SMA2011.14% SMA50-3.78% SMA2004.59% Volume217,960 Change4.24%
Jan-20-21Initiated Wedbush Outperform $65
Sep-29-20Initiated Cantor Fitzgerald Overweight $44
Aug-27-20Initiated H.C. Wainwright Buy $43
Apr-28-20Initiated SVB Leerink Outperform $45
Apr-28-20Initiated Morgan Stanley Overweight $45
Apr-28-20Initiated Jefferies Buy $41
Apr-28-20Initiated Guggenheim Buy $45
Feb-25-21 07:00AM  
Zentalis Pharmaceuticals and Tempus Announce Strategic Collaboration to Advance Research and Development Capabilities
GlobeNewswire
Feb-24-21 07:00AM  
Zentalis Pharmaceuticals to Present Initial Clinical Data on ZN-c3 at the AACR Annual Meeting 2021
GlobeNewswire +11.43%
Feb-10-21 07:00AM  
Zentalis Pharmaceuticals Announces the Appointment of Dr. Enoch Kariuki to its Board of Directors
GlobeNewswire
Feb-05-21 07:00AM  
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
GlobeNewswire
Feb-04-21 08:41AM  
Why Earnings Season Could Be Great for Zentalis (ZNTL)
Zacks
Jan-06-21 07:00AM  
Zentalis Pharmaceuticals Announces the Initiation of Multiple Early-Stage Clinical Trials
GlobeNewswire -6.54%
Dec-23-20 05:20AM  
Who Has Been Buying Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares?
Simply Wall St. +8.12%
Dec-12-20 10:19PM  
Is ZNTL A Good Stock To Buy Now?
Insider Monkey
Nov-12-20 07:00AM  
Zentalis Pharmaceuticals to Participate In Two Upcoming Investor Conferences
GlobeNewswire
Nov-09-20 07:00AM  
Zentalis Pharmaceuticals Reports Third Quarter 2020 Financial Results and Operational Update
GlobeNewswire -8.70%
Sep-23-20 01:59PM  
What Kind Of Investors Own Most Of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)?
Simply Wall St.
Sep-11-20 07:00AM  
Zentalis Pharmaceuticals to Host a Key Opinion Leader Virtual Meeting to Discuss its Investigational WEE1 Inhibitor ZN-c3 and its Potential as a Best-in-Class Treatment for Advanced Solid Tumors
GlobeNewswire
Sep-10-20 07:00AM  
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences
GlobeNewswire
Sep-01-20 07:00AM  
Zentalis Pharmaceuticals Appoints Alexis Pinto as Chief Legal Officer
GlobeNewswire -7.35%
Aug-13-20 07:00AM  
Zentalis Pharmaceuticals Reports Second Quarter 2020 Financial Results and Operational Update
GlobeNewswire
Jul-29-20 09:11PM  
Zentalis Pharmaceuticals Announces Pricing of Upsized Offering of Common Stock
GlobeNewswire
Jul-27-20 04:19PM  
Zentalis Pharmaceuticals Announces Proposed Public Offering of Common Stock
GlobeNewswire
07:00AM  
Zentalis Pharmaceuticals Enters into Clinical Collaboration with Eli Lilly and Company to Evaluate its Oral SERD ZN-c5 in Combination with Abemaciclib, a CDK4 and 6 Inhibitor
GlobeNewswire
Jul-01-20 07:00AM  
Zentalis Pharmaceuticals Announces the Appointment of Dr. Kimberly Blackwell to its Board of Directors
GlobeNewswire
Jun-15-20 04:30PM  
Zentalis Pharmaceuticals to Present Preclinical Data on ZN-c5 at the Upcoming AACR Virtual Annual Meeting II
GlobeNewswire +11.75%
Jun-03-20 07:07AM  
Is It Too Late to Jump In on Zentalis?
Motley Fool
May-28-20 04:05PM  
Zentalis Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference
GlobeNewswire
07:00AM  
Zentalis Pharmaceuticals and Tavros Therapeutics Announce Strategic Platform Collaboration to Discover Next Generation Targeted Small Molecule Therapies
GlobeNewswire
May-20-20 07:00AM  
Zentalis Pharmaceuticals Announces $20 Million Series A Financing to Establish a Chinese Joint Venture, Zentera Therapeutics
GlobeNewswire -8.04%
May-15-20 07:00AM  
Zentalis Pharmaceuticals Reports First Quarter 2020 Financial Results and Operational Update
GlobeNewswire -5.51%
May-13-20 09:30AM  
Morgan Stanley: 2 Stocks That Could Surge Over 25%
TipRanks
Apr-30-20 07:00AM  
Zentalis Pharmaceuticals Announces FDA Clearance of IND Application for ZN-d5 for the Treatment of Hematologic Malignancies
GlobeNewswire
Apr-07-20 04:05PM  
Zentalis Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
GlobeNewswire
Apr-02-20 09:22PM  
Zentalis Pharmaceuticals Announces Pricing of Initial Public Offering
GlobeNewswire
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small molecule therapeutics for the treatment of various cancers in the United States. Its lead product candidate is the ZN-c5, an oral selective estrogen receptor degrader that is in a Phase I/II clinical trial for the treatment of advanced or metastatic breast cancer. The company also develops ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase I/II clinical trial for the treatment of advanced solid tumors; ZN-d5, a selective inhibitor of B-cell lymphoma 2 for the treatment of hematological malignancies; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor that is in Phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. Zentalis Pharmaceuticals, Inc. was founded in 2014 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SUN ANTHONY YPresident & CEOFeb 01Sale37.5026,7941,004,8371,750,417Feb 03 05:56 PM
Gallagher CamDirectorFeb 01Sale37.4910,000374,865560,192Feb 03 05:55 PM
Epperly Melissa B,Chief Financial OfficerFeb 01Sale37.563,083115,805271,513Feb 03 05:56 PM
Bunker Kevin D.Chief Operating OfficerFeb 01Sale37.514,210157,91871,570Feb 03 05:55 PM
Bunker Kevin D.Chief Operating OfficerJan 04Sale51.978,420437,55975,780Jan 06 08:25 PM
Bunker Kevin D.Chief Operating OfficerJan 04Sale52.0826,5671,383,5581,025,713Jan 06 08:25 PM
Gallagher CamDirectorJan 04Sale51.9310,000519,323570,192Jan 06 08:25 PM
SUN ANTHONY YPresident & CEOJan 04Sale52.0626,7941,394,9071,777,211Jan 06 08:25 PM
Epperly Melissa B,Chief Financial OfficerJan 04Sale51.913,083160,034274,596Jan 06 08:24 PM
Gallagher CamDirectorDec 08Sale56.7522,5731,281,056580,192Dec 08 08:38 PM
Bunker Kevin D.Chief Operating OfficerDec 07Sale53.5210,892582,9541,053,880Dec 08 08:37 PM
Epperly Melissa B,Chief Financial OfficerDec 07Sale53.526,464345,963277,679Dec 08 08:38 PM
Gallagher CamDirectorDec 07Sale53.526,692358,166602,765Dec 08 08:38 PM
SUN ANTHONY YPresident & CEODec 07Sale53.5235,6061,905,6822,017,605Dec 08 08:37 PM
Bunker Kevin D.Chief Operating OfficerDec 04Sale50.9812,165620,2071,064,772Dec 08 08:37 PM
Epperly Melissa B,Chief Financial OfficerDec 04Sale50.987,220368,097284,143Dec 08 08:38 PM
Gallagher CamDirectorDec 04Sale50.987,474381,047609,457Dec 08 08:38 PM
SUN ANTHONY YPresident & CEODec 04Sale50.9839,7692,027,5402,053,211Dec 08 08:37 PM
Gallagher CamDirectorDec 02Sale51.4310,000514,334616,931Dec 03 05:56 PM
Johnson David MichaelDirectorDec 02Sale51.3912,896662,747101,752Dec 03 05:57 PM
Epperly Melissa B,Chief Financial OfficerDec 02Sale51.473,083158,681291,363Dec 03 05:56 PM
SUN ANTHONY YPresident & CEODec 02Sale51.4026,7941,377,3442,092,980Dec 03 05:56 PM
VIKING GLOBAL INVESTORS LP10% OwnerDec 01Sale50.50500,00025,250,0003,943,284Dec 03 06:30 PM
Bunker Kevin D.Chief Operating OfficerDec 01Sale52.968,420445,88384,200Dec 03 05:57 PM
SUN ANTHONY YPresident & CEONov 24Sale46.4511,386528,8442,119,774Nov 25 08:34 PM
Bunker Kevin D.Chief Operating OfficerNov 23Sale46.558,425392,17992,620Nov 25 08:34 PM
Epperly Melissa B,Chief Financial OfficerNov 23Sale46.583,083143,614294,446Nov 25 08:35 PM
SUN ANTHONY YPresident & CEONov 23Sale46.5315,408716,9202,131,160Nov 25 08:34 PM
Gallagher CamDirectorNov 23Sale46.5410,000465,381626,931Nov 25 08:33 PM
Johnson David MichaelDirectorApr 07Buy18.004,00072,000114,648Dec 03 05:57 PM
Bunker Kevin D.Chief Operating OfficerApr 07Buy18.003506,3001,177,982Nov 25 08:34 PM
Epperly Melissa B,Chief Financial OfficerApr 07Buy18.0020,000360,000297,529Nov 25 08:35 PM
SUN ANTHONY YPresident & CEOApr 07Buy18.0088815,9842,146,568Nov 25 08:34 PM
open in yahoo | open in reuters | open in google
affiliate • advertise • contact • privacy • help
Do not sell my personal information
Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2021 FINVIZ.com. All Rights Reserved.